E998: The Next Unicorns: Benchling CEO & Co-founder Sajith Wickramasekara is increasing efficiency for scientists with a cloud-based platform, gives insights on recent life-science innovations, ethics of gene therapy & defining the line between quackery & brilliance – E10 of 10-ep miniseries
This Week in Startups
Shifting Paradigms in Drug Development
This chapter explores the evolution of drug development, transitioning from traditional chemistry-based drugs to biologically-focused therapies. It examines the challenges in research and development, the advancements in immunotherapy and gene editing technologies, and the implications of innovative approaches like xenotransplantation. Ethical considerations surrounding gene editing practices, especially in human embryos, are also discussed, underscoring the complex interplay between scientific progress and moral dilemmas.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
